• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Optimization of therapeutic antibodies for reduced self-association and non-specific binding via interpretable machine learning

Optimization of therapeutic antibodies for reduced self-association and non-specific binding via interpretable machine learning

by Elena Iemma | Sep 6, 2023

Identification of immunodominant T cell epitopes induced by natural Zika virus infection

Identification of immunodominant T cell epitopes induced by natural Zika virus infection

by Elena Iemma | Aug 30, 2023

Immunogenicity risk assessment of synthetic peptide drugs and their impurities

Immunogenicity risk assessment of synthetic peptide drugs and their impurities

by Elena Iemma | Jul 27, 2023

Immunogenicity risk assessment of synthetic peptide drugs and their impurities – ScienceDirect

Comparison of Predicted T cell Epitopes in Porcine Circovirus Type 2 Isolates from 2017 to 2021 and Selected Vaccines (EpiCC Analysis) Confirms the Global Relevance of a Bivalent Vaccine Approach

by Elena Iemma | May 25, 2023

Comparison of Predicted T cell Epitopes in Porcine Circovirus Type 2 Isolates from 2017 to 2021 and Selected Vaccines (EpiCC Analysis) Confirms the Global Relevance of a Bivalent Vaccine Approach
Poster: Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Rare Diseases

Poster: Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Rare Diseases

by Elena Iemma | Nov 4, 2022

« Older Entries
Next Entries »

Recent Posts

  • The Platinum Vaccine & Change is Good!
  • EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO
  • Smarter Tools, Safer Therapies: Supporting the FDA’s Roadmap with in silico Immunogenicity Assessment
  • The Amsterdam Immunogenicity & Tolerance Seminar: 2025
  • The Westin Immunogenicity Seminar

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CMO, Dr. Annie De Groot.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.